Concepedia

Brian M. Lacey

BM

Statistics

Publications

19

Citations

1.8K

H-Index

19

Active since

1951

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Quantitative BioSciences

Pfizer (United States)

University of Vermont

United States Military Academy

Brian M. Lacey is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, life sciences, and drug discovery.

Publications per year

1951–2022

19

Publications

19

An orally available non-nucleotide STING agonist with antitumor activity

Bo‐Sheng Pan, Samanthi A. Perera, Jennifer Piesvaux et al. · Science · 2020 · 660 citations

Medicine, Medicinal Chemistry, Pharmacology +16

Discovery of a Novel cGAMP Competitive Ligand of the Inactive Form of STING

Tony Siu, Michael D. Altman, Gretchen A. Baltus et al. · ACS Medicinal Chemistry Letters · 2018 · 172 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of <i>Pseudomonas aeruginosa</i>

Seungil Han, Richard P. Zaniewski, Eric S. Marr et al. · Proceedings of the National Academy of Sciences · 2010 · 161 citations · Full text

Life Sciences, Microbiology, Pharmacology +16

Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer

Wonsuk Chang, Michael D. Altman, Charles A. Lesburg et al. · Journal of Medicinal Chemistry · 2022 · 137 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Clinically Relevant Gram-Negative Resistance Mechanisms Have No Effect on the Efficacy of MC-1, a Novel Siderophore-Conjugated Monocarbam

Craig J. McPherson, Lisa Aschenbrenner, Brian M. Lacey et al. · Antimicrobial Agents and Chemotherapy · 2012 · 89 citations · Full text

Life Sciences, Medicinal Chemistry, Antimicrobial Resistance +16

1–5 of 19